Telo Genomics Announces Private Placement for up to $2 Million
Telo Genomics Corp. (TSXV: TELO, OTCQB: TDSGF, FSE: 3DOA) has announced a non-brokered private placement of units priced at $0.10 each, aiming to raise up to $2,000,000 in gross proceeds. Each unit includes one common share and one non-transferable common share purchase warrant. The warrant allows the holder to purchase an additional common share at $0.15 per share for up to 36 months, with an acceleration clause if the share price reaches $0.40 for ten consecutive trading days. The company may pay finder's fees up to 7% of the gross proceeds and issue finder's warrants equal to 7% of the units sold. The proceeds will be used for general working capital. The securities will be subject to a four-month hold period and are not registered under the United States Securities Act of 1933.
Telo Genomics Corp. (TSXV: TELO, OTCQB: TDSGF, FSE: 3DOA) ha annunciato un collocamento privato senza intermediari di unità al prezzo di $0,10 ciascuna, con l'obiettivo di raccogliere fino a $2.000.000 in proventi lordi. Ciascuna unità comprende una azione comune e un warrant non trasferibile per l'acquisto di azioni comuni. Il warrant consente al titolare di acquistare un'ulteriore azione comune a $0,15 per azione per un massimo di 36 mesi, con una clausola di accelerazione se il prezzo dell'azione raggiunge $0,40 per dieci giorni di trading consecutivi. L'azienda può pagare commissioni per l'intermediazione fino al 7% dei proventi lordi e rilasciare warrant per l'intermediazione pari al 7% delle unità vendute. I proventi saranno utilizzati per il capitale di lavoro generale. I titoli saranno soggetti a un periodo di blocco di quattro mesi e non sono registrati ai sensi del Securities Act degli Stati Uniti del 1933.
Telo Genomics Corp. (TSXV: TELO, OTCQB: TDSGF, FSE: 3DOA) ha anunciado una colocación privada no intermediada de unidades a un precio de $0.10 cada una, con el objetivo de recaudar hasta $2,000,000 en ingresos brutos. Cada unidad incluye una acción común y una opción de compra no transferible de acciones comunes. La opción permite al titular comprar una acción común adicional a $0.15 por acción durante un máximo de 36 meses, con una cláusula de aceleración si el precio de la acción alcanza los $0.40 durante diez días de negociación consecutivos. La empresa puede pagar comisiones de intermediación de hasta el 7% de los ingresos brutos y emitir opciones de compra de intermediación equivalentes al 7% de las unidades vendidas. Los ingresos se utilizarán para el capital de trabajo general. Los valores estarán sujetos a un periodo de bloqueo de cuatro meses y no están registrados bajo la Ley de Valores de Estados Unidos de 1933.
Telo Genomics Corp. (TSXV: TELO, OTCQB: TDSGF, FSE: 3DOA)는 각각 $0.10에 가격이 책정된 비대리사 사모 발행을 발표하며, 최대 $2,000,000의 총 수익을 목표로 하고 있습니다. 각 유닛은 하나의 보통주와 양도할 수 없는 보통주 매수 권리를 포함하고 있습니다. 이 권리는 보유자가 $0.15에 추가 보통주를 36개월 이내에 구매할 수 있도록 하며, 주가가 10일 연속으로 $0.40에 이를 경우 가속 조항이 적용됩니다. 회사는 총 수익의 최대 7%에 해당하는 중개 수수료를 지급할 수 있으며, 판매된 유닛의 7%에 해당하는 중개권을 발행할 수 있습니다. 수익금은 일반 운영 자본으로 사용될 것입니다. 증권은 4개월의 보유 기간이 적용될 것이며, 1933년 미국 증권법에 따라 등록되지 않습니다.
Telo Genomics Corp. (TSXV: TELO, OTCQB: TDSGF, FSE: 3DOA) a annoncé un placement privé non intermédié d'unités au prix de 0,10 $ chacune, visant à lever jusqu'à 2 000 000 $ de produits bruts. Chaque unité comprend une action ordinaire et un bon de souscription d'actions ordinaires non transférable. Le bon permet au détenteur d'acheter une action ordinaire supplémentaire à 0,15 $ par action pendant une période maximale de 36 mois, avec une clause d'accélération si le prix de l'action atteint 0,40 $ pendant dix jours de bourse consécutifs. La société peut verser des frais de courtage jusqu'à 7 % des produits bruts et émettre des bons de courtage équivalents à 7 % des unités vendues. Les produits seront utilisés pour le fonds de roulement général. Les titres seront soumis à une période de détention de quatre mois et ne sont pas enregistrés en vertu de la Loi de 1933 sur les valeurs mobilières des États-Unis.
Telo Genomics Corp. (TSXV: TELO, OTCQB: TDSGF, FSE: 3DOA) hat eine nicht vermittelte Privatplatzierung von Einheiten zu einem Preis von 0,10 $ angekündigt, mit dem Ziel, bis zu 2.000.000 $ an Bruttoeinnahmen zu erzielen. Jede Einheit besteht aus einer Stammaktie und einer nicht übertragbaren Kaufoption für Stammaktien. Die Option ermöglicht es dem Inhaber, innerhalb von 36 Monaten eine zusätzliche Stammaktie zu einem Preis von 0,15 $ pro Aktie zu kaufen, mit einer Beschleunigungsklausel, wenn der Aktienkurs zehn aufeinanderfolgende Handelstage lang 0,40 $ erreicht. Das Unternehmen kann Vermittlungsgebühren von bis zu 7 % der Bruttoeinnahmen zahlen und Vermittlungsoptionen in Höhe von 7 % der verkauften Einheiten ausgeben. Die Einnahmen werden für das allgemeine Betriebskapital verwendet. Die Wertpapiere unterliegen einer Sperrfrist von vier Monaten und sind nicht gemäß dem United States Securities Act von 1933 registriert.
- Potential to raise up to $2,000,000 in gross proceeds.
- Warrants provide an opportunity for additional capital if exercised.
- Finder's fees and warrants could incentivize more investment.
- Dilution of existing shareholder value due to new share issuance.
- Potential expiration of warrants if not exercised within the specified period.
Toronto, Ontario--(Newsfile Corp. - December 12, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) (the "Company" or "Telo") is pleased to announce a non-brokered private placement of units ("Units") at a price of
Each Unit will consist of one common share of the Company (a "Common Share") and one non-transferable common share purchase warrant (a "Warrant"). Each Warrant will entitle the holder to acquire one additional Common Share at a price of
The Warrants are subject to an acceleration right held by the Company, such that if, at any time after one year after the date of issuance of the Warrants, the share price closes at
In connection with the Offering, the Company may pay finder's fees to eligible arm's length parties. The finder's fees may consist of a cash fee equal to
The Company intends to use the net proceeds of the Offering for general working capital purposes.
All securities to be issued pursuant to the Offering will be subject to a four-month hold period from the date of issuance, in accordance with applicable securities laws. The Offering is subject to TSX Venture Exchange acceptance.
The securities offered have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or applicable exemption from the registration requirements. This news release does not constitute an offer to sell or the solicitation of any offer to buy nor will there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such province, state or jurisdiction.
About TELO
Telo Genomics Corp. is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, TELO-MM is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.
For further information, please contact:
Sherif Louis
President & CTO
Telo Genomics
416-673-8487
www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the Offering, the use of proceeds, receipt of TSX-V acceptance, and the payment of finder's fees are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/233447
FAQ
What is the TDSGF private placement offering?
What is the duration for the TDSGF warrants?
What are the finder's fees in the TDSGF offering?
How will Telo Genomics use the proceeds from the private placement?
Are the TDSGF securities subject to any hold period?